Cargando…
Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
BACKGROUND: Although many acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients have been treated with hypomethylating agents (HMAs) as a substitute for intensive chemotherapy in recent years, the incidence of invasive fungal infections (IFIs) and the efficacy of posaconazole as a...
Autores principales: | Kang, Ka-Won, Lee, Byung-Hyun, Jeon, Min Ji, Yu, Eun Sang, Sik Kim, Dae, Lee, Se Ryeon, Sung, Hwa Jung, Choi, Chul Won, Park, Yong, Kim, Byung Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832331/ https://www.ncbi.nlm.nih.gov/pubmed/35154623 http://dx.doi.org/10.1177/2040620720966882 |
Ejemplares similares
-
Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
por: Lee, Byung-Hyun, et al.
Publicado: (2020) -
Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021) -
Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021) -
Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020) -
No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)